• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed

    2/12/21 8:30:10 AM ET
    $CVLB
    Get the next $CVLB alert in real time by email
    8-K 1 form8-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 11, 2021

     

    CONVERSION LABS, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-39785   76-0238453

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    800 Third Avenue, Suite 2800

    New York, NY 10022

    (Address of principal executive offices, including zip code)

     

    (866) 351-5907

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    [  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    [  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    [  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    [  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Title of each class   Trading Symbol(s)  

    Name of each exchange on which registered

    Common Stock   CVLB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company [  ]

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

     

     

     

     
       

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Securities Purchase Agreement

     

    On February 11, 2021 (the “Closing Date”), Conversion Labs, Inc., a Delaware corporation (the “Company”), consummated the closing of a private placement offering (the “Offering”), whereby pursuant to the securities purchase agreement (the “Purchase Agreement”) entered into by the Company and certain accredited investors on February 11, 2021 (each an “Investor” and collectively, the “Investors”) the Investors purchased 608,696 shares of the Company’s common stock par value $0.01 per share (the “Common Stock”), at a purchase price of $23.00 per share for aggregate gross proceeds of $14,000,008.00 (the “Purchase Price”).

     

    The Purchase Price was funded on the Closing Date and resulted in net proceeds to the Company of approximately $13.4 million after deducting fees payable to the placement agent and other estimated offering expenses payable by the Company.

     

    BTIG, LLC (the “Placement Agent”) acted as exclusive placement agent for the Offering and received cash compensation equal to 3% of the Purchase Price.

     

    Registration Rights Agreement

     

    On February 11, 2021, in connection with the Purchase Agreement, the Company entered into a registration rights agreement with the Investors (the “Registration Rights Agreement”). The Registration Rights Agreement requires the Company to use its reasonable best efforts to register the resale of the Shares by the Investors on Form S-1 to be filed with the Securities and Exchange Commission (‘SEC”), under the Securities Act of 1933, as amended (the “Securities Act”), within 60 business days from the Closing Date, and to use its reasonable best efforts to have such registration statement declared effective by the SEC as soon as practicable, but not later than 120 days from the Closing Date (or 150 days from the Closing Date in the event that such registration statement is subject to a full review by the SEC).

     

    The foregoing provides only brief descriptions of the material terms of the Purchase Agreement and the Registration Rights Agreement, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the full text of the forms of the Purchase Agreement and the Registration Rights Agreement filed as exhibits to this Current Report on Form 8-K, and are incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The applicable information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02.

     

    The Shares referred to in this Current Report on Form 8-K are being issued and sold by the Company to the Investors, in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. Each of the Investors has represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act).

     

    Item 8.01 Other Events.

     

    On February 12, 2021, the Company issued a press release announcing the Offering. A Copy of the press release is filed hereto as Exhibits 99.1 and is incorporated herein by reference.

     

    Item 9.01 Financial Statement and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Exhibit
    10.1   Form of Securities Purchase Agreement
    10.2   Form of Registration Rights Agreement
    99.1   Press Release, dated February 11, 2021

     

     
       

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CONVERSION LABS INC..
         
    Date: February 12, 2021 By: /s/ Justin Schreiber
      Name:  Justin Schreiber
      Title: Chief Executive Officer

     

     

     

    Get the next $CVLB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVLB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: David Happy Walters was granted 1,200,000 units of Common Stock, increasing ownership by 149% to 1,336,300 units

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/26/21 10:04:47 AM ET
      $CVLB
    • SEC Form 4: Harold Eric Yecies bought $100,400 worth of Common Stock (5,000 units at $20.08)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 7:16:47 PM ET
      $CVLB
    • SEC Form 4: Michael Brad Roberts bought $102,500 worth of Common Stock (5,000 units at $20.50)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 6:13:10 PM ET
      $CVLB

    $CVLB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD

      NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock’s new CUSIP number will be 53216B 104. “Our new name reflects our evolution from a healthcare-focused performance marketing business into a leading provider of personalized, direct to patient telehealth services,” stated Justin Schreiber, LifeMD’s co-founder and CEO. “Our vision is to radically change healthcare by making access to the best physicians and prescription medications easily accessible, convenient, and aff

      2/22/21 3:30:00 AM ET
      $CVLB
    • Conversion Labs to Become Life MD™ with Launch of New Concierge Telehealth Services

      NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare. “We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more conven

      2/12/21 8:30:00 AM ET
      $CVLB
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB

    $CVLB
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - LifeMD, Inc. (0000948320) (Filer)

      2/26/21 5:00:48 PM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/22/21 7:30:16 AM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/12/21 8:30:10 AM ET
      $CVLB

    $CVLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Conversion Labs with a new price target

      BTIG Research reiterated coverage of Conversion Labs with a rating of Buy and set a new price target of $40.00 from $15.00 previously

      2/18/21 9:19:07 AM ET
      $CVLB
    • B. Riley FBR initiated coverage on Conversion Labs with a new price target

      B. Riley FBR initiated coverage of Conversion Labs with a rating of Buy and set a new price target of $35.00

      2/5/21 6:59:45 AM ET
      $CVLB

    $CVLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CVLB
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13D filed by Conversion Labs, Inc.

      SC 13D - LifeMD, Inc. (0000948320) (Subject)

      3/19/21 4:15:12 PM ET
      $CVLB
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

      NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals. Dr. Puopolo brings to Conversion Labs more than 20 years of execut

      1/11/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

      NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value. Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and custo

      1/5/21 10:15:00 AM ET
      $CVLB